Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
- About
Translational Development Acquisition Corp. Ordinary Shares (TDAC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: TDAC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $0
1 Year Target Price $0
| 0 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 219.95M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 10.00 - 10.28 | Updated Date 05/1/2025 |
52 Weeks Range 10.00 - 10.28 | Updated Date 05/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.03 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 220386003 | Price to Sales(TTM) - |
Enterprise Value 220386003 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 17250000 | Shares Floating 3032762 |
Shares Outstanding 17250000 | Shares Floating 3032762 | ||
Percent Insiders - | Percent Institutions 7.54 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Translational Development Acquisition Corp. Ordinary Shares
Company Overview
History and Background
Translational Development Acquisition Corp. was a special purpose acquisition company (SPAC) formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. It has since completed its business combination.
Core Business Areas
- SPAC: The company's initial core business was acting as a SPAC to identify and acquire a private company.
Leadership and Structure
As a SPAC, leadership typically included a team of experienced investors and dealmakers. The organizational structure was designed to facilitate the identification, evaluation, and acquisition of a target company.
Top Products and Market Share
Key Offerings
- SPAC Activity: The primary offering was the promise of identifying and acquiring a promising private company, allowing public market investors access to a potentially high-growth opportunity. Market share is not applicable as it was a SPAC prior to merger. Competitors include other SPACs.
Market Dynamics
Industry Overview
The SPAC market has been characterized by periods of high activity followed by periods of increased scrutiny and regulatory changes.
Positioning
Translational Development Acquisition Corp. aimed to differentiate itself based on the expertise of its management team and its focus on specific industries. Its ultimate positioning depended on the target company acquired.
Total Addressable Market (TAM)
The TAM for SPACs is difficult to quantify as it depends on the universe of private companies seeking to go public. Translational Development Acquisition Corp. aimed to capture a portion of this TAM through a successful acquisition.
Upturn SWOT Analysis
Strengths
- Experienced management team
- Access to public market capital
- Potential for high growth through acquisition
Weaknesses
- Dependence on identifying a suitable target
- Dilution of existing shareholders
- Regulatory risks associated with SPACs
Opportunities
- Growing demand for alternative routes to public markets
- Availability of attractive acquisition targets
- Potential for value creation through operational improvements
Threats
- Increased competition from other SPACs
- Changing regulatory landscape
- Economic downturn affecting acquisition targets
Competitors and Market Share
Key Competitors
Competitive Landscape
Translational Development Acquisition Corp.'s competitive advantage depended on the attractiveness of its management team and its deal-sourcing capabilities.
Growth Trajectory and Initiatives
Historical Growth: Growth as a SPAC was dependent on identifying and acquiring a suitable target.
Future Projections: Future projections are dependent on the acquired company's performance.
Recent Initiatives: The key initiative was the completion of the business combination with a target company.
Summary
Translational Development Acquisition Corp. functioned as a special purpose acquisition company to merge with another company. The strength of the company relied upon the successful identification and merger of a promising business. Now that the combination is complete, its success depends on the acquired company's long term growth, but it needed to manage risks of market competition. Changes in regulations could also impact the company's operations.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Financial News Outlets
Disclaimers:
This analysis is based on publicly available information and is not financial advice. The SPAC market is inherently risky, and past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Translational Development Acquisition Corp. Ordinary Shares
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2025-02-13 | Chairman of the Board & CEO Mr. Michael M. B. Hoffman J.D. | ||
Sector Financial Services | Industry Shell Companies | Full time employees - | |
Full time employees - | |||
Translational Development Acquisition Corp. does not have significant operations. It intends to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. Translational Development Acquisition Corp. was incorporated in 2022 and is based in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.